The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis
Abstract
Purpose: Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for brain metastases in patients with EGFR-mutant non–small-cell lung cancer (NSCLC). This multi-institutional analysis sought to determine the optimal management of patients with EGFR-mutant NSCLC who develop brain metastases and have not received EGFR-TKI. Materials and Methods: A total of 351 patients from six institutions with EGFR-mutant NSCLC developed brain metastases and met inclusion criteria for the study. Exclusion criteria included prior EGFR-TKI use, EGFR-TKI resistance mutation, failure to receive EGFR-TKI after WBRT/SRS, or insufficient follow-up. Patients were treated with SRS followed by EGFR-TKI, WBRT followed by EGFR-TKI, or EGFR-TKI followed by SRS or WBRT at intracranial progression. Overall survival (OS) and intracranial progression-free survival were measured from the date of brain metastases. Results: The median OS for the SRS (n = 100), WBRT (n = 120), and EGFR-TKI (n = 131) cohorts was 46, 30, and 25 months, respectively ( P < .001). On multivariable analysis, SRS versus EGFR-TKI, WBRT versus EGFR-TKI, age, performance status, EGFR exon 19 mutation, and absence of extracranial metastases were associated with improved OS. Although the SRS and EGFR-TKI cohorts shared similar prognostic features, the WBRT cohort was more likely to have a less favorable prognosis ( P = .001). Conclusion: This multi-institutional analysis demonstrated that the use of upfront EGFR-TKI, and deferral of radiotherapy, is associated with inferior OS in patients with EGFR-mutant NSCLC who develop brain metastases. SRS followed by EGFR-TKI resulted in the longest OS and allowed patients to avoid the potential neurocognitive sequelae of WBRT. A prospective, multi-institutional randomized trial of SRS followed by EGFR-TKI versus EGFR-TKI followed by SRS at intracranial progression is urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Chang, E. L., Wefel, J. S., Hess, K. R., Allen, P. K., Lang, F. F., Kornguth, D. G., Arbuckle, R. B., Swint, J. M., Shiu, A. S., Maor, M. H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70263-3 · Cited by 2,475
Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, R. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.149 · Cited by 1,843
Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., Yamanaka, K., Sato, Y., Jokura, H., Yomo, S., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70061-0 · Cited by 1,447
Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425
Self-citationHan, J.-Y., Park, K., Kim, S.-W., Lee, D. H., Kim, H. Y., Kim, H. T., Ahn, M. J., Yun, T., Ahn, J. S., Suh, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8456 · Cited by 736
Soffietti, R., Kocher, M., Abacioglu, U. M., Villa, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0639 · Cited by 636
The biology of brain metastases—translation to new therapies
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.58 · Cited by 567
The revised TNM staging system for lung cancer.
Rami–Porta, R., Crowley, J. J., & Goldstraw, P. G. (2009) · PubMed · Cited by 442
Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., Congedo, M. T., Gomez, D. R., Wright, G. M., Melloni, G., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.04.003 · Cited by 435
Yu, H. A., Sima, C. S., Huang, J., Solomon, S. B., Rimner, A., Paik, P., Pietanza, M. C., Azzoli, C. G., Rizvi, N. A., Krug, L. M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827e1f83 · Cited by 341
Fink, K., & Fink, J. (2013) · Surgical Neurology International · doi:10.4103/2152-7806.111298 · Cited by 333
Park, S. J., Kim, H. T., Lee, D. H., Kim, K. P., Kim, S.-W., Suh, C., & Lee, J. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.05.092 · Cited by 321
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Shin, D.-Y., Na, I. I., Kim, C. H., Park, S., Baek, H., & Yang, S. H. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000069 · Cited by 319
Ashworth, A., Rodrigues, G., Boldt, G., & Palma, D. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.026 · Cited by 282
Iuchi, T., Shingyoji, M., Sakaida, T., Hatano, K., Nagano, O., Itakura, M., Kageyama, H., Yokoi, S., Hasegawa, Y., Kawasaki, K., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.016 · Cited by 257
Wu, Y.-L., Zhou, C., Cheng, Y., Lu, S., Chen, G.-Y., Huang, C., Huang, Y.-S., Yan, H.-H., Ren, S., Liu, Y., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds529 · Cited by 234
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
Li, C., Fang, R., Sun, Y., Han, X., Li, F., Gao, B., Iafrate, A. J., Liu, X.-Y., Pao, W., Chen, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028204 · Cited by 230
Spano, J. P., Fagard, R., Soria, J.-C., Rixe, O., Khayat, D., & Milano, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi057 · Cited by 195
Khozin, S., Blumenthal, G. M., Jiang, X., He, K., Boyd, K. K., Murgo, A. J., Justice, R. L., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0089 · Cited by 150
Soon, Y. Y., Leong, C. N., Koh, W. Y., & Tham, I. W. K. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.12.011 · Cited by 110
Habets, E. J. J., Dirven, L., Wiggenraad, R. G. J., Kanter, A. V.-D., Nijeholt, G. J. L. À., Zwinkels, H., Klein, M., & TAPHOORN, M. J. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov186 · Cited by 110
Magnuson, W. J., Yeung, J. T., Guillod, P., Gettinger, S. N., Yu, J. B., & Chiang, V. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.01.037 · Cited by 104
Self-citationGerber, N. K., Yamada, Y., Rimner, A., Shi, W., Riely, G. J., Beal, K., Yu, H. A., Chan, T. A., Zhang, Z., & Wu, A. J. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.02.022 · Cited by 96
Self-citationA Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer
Johung, K. L., Yao, X., Li, F., Yu, J. B., Gettinger, S. N., Goldberg, S. B., Decker, R. H., Hess, J. A., Chiang, V., & Contessa, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0836 · Cited by 95
Self-citationWang, T. J. C., Saad, S., Qureshi, Y. H., Jani, A., Nanda, T., Yaeh, A. M., Rozenblat, T., Sisti, M. B., Bruce, J. N., McKhann, G. M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov043 · Cited by 44
Cited by
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, M. A., Brown, P. D., Messersmith, H., Brastianos, P. K., Burri, S., Cahill, D., Dunn, I. F., Gaspar, L. E., Gatson, N. T. N., Gondi, V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02314 · Cited by 832
Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637
Le Rhun, E., Guckenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., Galldiks, N., de Azambuja, E., Berghoff, A. S., Metellus, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.016 · Cited by 592
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Overview of current systemic management of EGFR-mutant NSCLC
Hsu, W.-H., Yang, J. C.-H., Mok, T. S., & Loong, H. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx702 · Cited by 388
Metadata
- Authors
- Magnuson, W. J., Lester-Coll, N. H., Wu, A. J., Yang, T. J., Lockney, N. A., Gerber, N. K., Beal, K., Amini, A., Patil, T., Kavanagh, B. D., Camidge, D. R., Braunstein, S. E., Boreta, L. C., Balasubramanian, S. K., Ahluwalia, M. S., Rana, N. G., Attia, A., Gettinger, S. N., Contessa, J. N., Yu, J. B., & Chiang, V. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-04-01
- Volume
- 35
- Issue
- 10
- Pages
- 1070-1077
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2581511343
- Cited by
- 461
- References
- 29
- FWCI
- 40.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.